Acadia Pharmaceuticals Delivers Record Q3 Revenue, Fueled by Antipsychotic Drug Nuplazid

Acadia Pharmaceuticals (NASDAQ: ACAD) has been a huge winner so far in 2019. The biotech's Parkinson's disease psychosis (PDP) medicine Nuplazid (pimavanserin) has picked up significant sales momentum, and it's reported some positive clinical results.

The company announced its third-quarter results after the market closed on Wednesday. And Acadia had even more good news. Here are the highlights from the drugmaker's Q3 update.

Image source: Getty Images.

Continue reading

Source Fool.com